Discover a clinically predictive and reproducible platform developed by The Jackson Laboratory for simultaneous efficacy and safety assessment. This platform identifies patient-therapy combinations at risk of developing severe inflammatory syndrome, a potentially fatal complication. Optimise the safety profiles of your immunomodulatory therapeutics before first-in-human trials by leveraging this platform.
In this bispecific case study, learn how the platform:
Seize this opportunity to gain valuable insights into the future of efficient preclinical drug discovery and development.
Brought to you by